MA41350A - Synthèse d'un inhibiteur de la tyrosine kinase de bruton - Google Patents

Synthèse d'un inhibiteur de la tyrosine kinase de bruton

Info

Publication number
MA41350A
MA41350A MA041350A MA41350A MA41350A MA 41350 A MA41350 A MA 41350A MA 041350 A MA041350 A MA 041350A MA 41350 A MA41350 A MA 41350A MA 41350 A MA41350 A MA 41350A
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitor
bruton tyrosine
bruton
inhibitor
Prior art date
Application number
MA041350A
Other languages
English (en)
French (fr)
Inventor
Cyril Benhaim
Wei Chen
Erick Goldman
Andras Horvath
Philip Pye
Mark S Smyth
Erik J Verner
Original Assignee
Janssen Pharmaceutica Nv
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Pharmacyclics Llc filed Critical Janssen Pharmaceutica Nv
Publication of MA41350A publication Critical patent/MA41350A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA041350A 2015-01-14 2016-01-13 Synthèse d'un inhibiteur de la tyrosine kinase de bruton MA41350A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14

Publications (1)

Publication Number Publication Date
MA41350A true MA41350A (fr) 2017-11-21

Family

ID=56406389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041350A MA41350A (fr) 2015-01-14 2016-01-13 Synthèse d'un inhibiteur de la tyrosine kinase de bruton

Country Status (16)

Country Link
US (6) US20180009814A1 (enExample)
EP (1) EP3245208A4 (enExample)
JP (2) JP2018502077A (enExample)
KR (1) KR20170102887A (enExample)
CN (2) CN113816962A (enExample)
AU (2) AU2016206693A1 (enExample)
BR (1) BR112017015206B1 (enExample)
CA (2) CA3210320A1 (enExample)
HK (1) HK1246293A1 (enExample)
IL (4) IL322449A (enExample)
MA (1) MA41350A (enExample)
MX (2) MX366827B (enExample)
RU (1) RU2017128308A (enExample)
SG (2) SG11201705678YA (enExample)
WO (1) WO2016115356A1 (enExample)
ZA (1) ZA201704338B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207519B (zh) * 2015-02-12 2019-11-08 正大天晴药业集团股份有限公司 伊布替尼的制备方法
JP7085985B2 (ja) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
CN110944999A (zh) * 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
KR102473372B1 (ko) 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 알킬황산나트륨을 포함하는 의약 조성물
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
JP6944496B2 (ja) 2018-10-22 2021-10-06 ファイザー・インク ピロロ[2,3−d]ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
WO2020095452A1 (ja) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希(南京)药物研发有限公司 一种依鲁替尼-d5的制备方法
JP7658916B2 (ja) * 2019-05-21 2025-04-08 ヤンセン ファーマシューティカ エヌ.ベー. Btk阻害剤を調製するためのプロセス及び中間体
KR20220011669A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
CA2548374C (en) * 2003-12-23 2014-05-27 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
ES2616789T3 (es) * 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
ES2562215T3 (es) * 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US9422295B2 (en) * 2012-07-30 2016-08-23 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Also Published As

Publication number Publication date
IL274716A (en) 2020-07-30
CN113816962A (zh) 2021-12-21
US20220098200A1 (en) 2022-03-31
EP3245208A1 (en) 2017-11-22
US20180009814A1 (en) 2018-01-11
CA2971460C (en) 2023-10-10
CA3210320A1 (en) 2016-07-21
JP2018502077A (ja) 2018-01-25
IL322449A (en) 2025-09-01
KR20170102887A (ko) 2017-09-12
MX366827B (es) 2019-07-25
BR112017015206A2 (pt) 2018-06-19
IL253020A0 (en) 2017-08-31
BR112017015206B1 (pt) 2023-04-11
AU2016206693A1 (en) 2017-07-13
EP3245208A4 (en) 2018-10-17
US20250197404A1 (en) 2025-06-19
JP2021035947A (ja) 2021-03-04
RU2017128308A3 (enExample) 2019-10-24
US20200347064A1 (en) 2020-11-05
SG11201705678YA (en) 2017-08-30
ZA201704338B (en) 2023-10-25
US20190367518A1 (en) 2019-12-05
CN107108640A (zh) 2017-08-29
IL308276A (en) 2024-01-01
WO2016115356A1 (en) 2016-07-21
MX2017009154A (es) 2017-10-12
HK1246293A1 (zh) 2018-09-07
CA2971460A1 (en) 2016-07-21
AU2020230323A1 (en) 2020-10-01
US20240158400A1 (en) 2024-05-16
MX2019008815A (es) 2019-09-26
RU2017128308A (ru) 2019-02-14
MX394327B (es) 2025-03-24
SG10201906517VA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
ZA201907661B (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
MA41828A (fr) Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
EP3405192A4 (en) BRUTON TYROSINE KINASE HEMMER
MA42242A (fr) Inhibiteurs de la tyrosine kinase
IL248546B (en) A multi-fluorinated compound as an inhibitor of proton tyrosine kinase
DK3303334T3 (da) Tyrosinkinasehæmmere
HUE050842T2 (hu) Janus-kináz inhibitor
PL3423059T3 (pl) Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
MA41827A (fr) Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
EP3141546A4 (en) Inhibitor of bruton's tyrosine kinase
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
EP3159340A4 (en) New bruton's tyrosine kinase inhibitor
HUE066253T2 (hu) Benzoazepin analógok a bruton tirozin kináz gátlószereként
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
MA42510A (fr) Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
MA42546A (fr) Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations
EP3511327A4 (en) TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF
EP3882241A4 (en) INHIBITOR OF BRUTON TYROSINE KINASE
EP3387469A4 (en) ELEKTROFAZIENBESTIMMUNG
EP3412657A4 (en) NOVEL IRREVERSIBLE BRUTON TYROSINE KINASE INHIBITORS